Patents by Inventor Leyuan Ma

Leyuan Ma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS FOR CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY AND USES THEREOF
    Publication number: 20240082373
    Abstract: The disclosure features amphiphilic ligand conjugates comprising a chimeric antigen receptor (CAR)ligand and a lipid. The disclosure also features compositions and methods of using the same, for example, to stimulate proliferation of CAR expressing cells.
    Type: Application
    Filed: June 21, 2023
    Publication date: March 14, 2024
    Inventors: Darrell J. IRVINE, Leyuan Ma
  • SOLUBLE MULTIMERIC IMMUNOGLOBULIN-SCAFFOLD BASED FUSION PROTEINS AND USES THEREOF
    Publication number: 20220275043
    Abstract: The present disclosure provides soluble, multimeric fusion proteins that bind to a component of the MHC/TCR immune complex, wherein the fusion proteins comprise a soluble T cell receptor (TCR) or soluble Major Histocompatibility Complex (MHC) linked to an immunoglobulin framework by a multimerization domain. The disclosure also features compositions and methods of using the same for therapeutic or diagnostic use.
    Type: Application
    Filed: July 17, 2019
    Publication date: September 1, 2022
    Inventors: Darrell J. IRVINE, Leyuan MA
  • METHODS FOR IDENTIFYING CHIMERIC ANTIGEN RECEPTOR-TARGETING LIGANDS AND USES THEREOF
    Publication number: 20210340524
    Abstract: The disclosure features chimeric antigen receptor (CAR) ligands, methods for making the same, and immunomodulatory compositions comprising the CAR ligands. The disclosure also features compositions and methods of using the immunomodulatory compositions, for example, to stimulate activation of CAR expressing cells.
    Type: Application
    Filed: March 1, 2021
    Publication date: November 4, 2021
    Inventors: Darrell J. IRVINE, Karl Dane WITTRUP, Naveen MEHTA, Leyuan MA, Benjamin COSSETTE
  • CHIMERIC ANTIGEN RECEPTOR-TARGETING LIGANDS AND USES THEREOF
    Publication number: 20210338833
    Abstract: The disclosure features chimeric antigen receptor (CAR) ligands, methods for making the same, and immunomodulatory compositions comprising the CAR ligands. The disclosure also features compositions and methods of using the immunomodulatory compositions, for example, to stimulate activation of CAR expressing cells.
    Type: Application
    Filed: March 1, 2021
    Publication date: November 4, 2021
    Inventors: Darrell J. IRVINE, Karl Dane WITTRUP, Naveen MEHTA, Leyuan MA, Benjamin COSSETTE
  • COMPOSITIONS FOR CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY AND USES THEREOF
    Publication number: 20200230221
    Abstract: The disclosure describes amphiphilic ligand conjugates comprising a chimeric antigen receptor (CAR) ligand, a lipid (diacyl lipid), a linker (hydrophilic polymers, hydrophilic amino acids, polysaccharides), compositions and methods of using the constructs are claimed, for example, to stimulate proliferation of CAR expressing cells.
    Type: Application
    Filed: September 19, 2018
    Publication date: July 23, 2020
    Inventors: Darrell J. IRVINE, Leyuan MA
  • Treating chronic myelogenous leukemia (CML)
    Patent number: 10428387
    Abstract: Methods for treating chronic myeloid leukemia (CML), e.g., BCR-ABL inhibitor imatinib mesylate (IM)-resistant CML, using combination treatments, e.g., combined treatment with a BCR-ABL inhibitor, e.g., IM, and a MEK inhibitor, e.g., trametinib.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: October 1, 2019
    Assignee: University of Massachusetts
    Inventors: Michael R. Green, Leyuan Ma
  • Treating Chronic Myelogenous Leukemia (CML)
    Publication number: 20170183741
    Abstract: Methods for treating chronic myeloid leukemia (CML), e.g., BCR-ABL inhibitor imatinib mesylate (IM)-resistant CML, using combination treatments, e.g., combined treatment with a BCR-ABL inhibitor, e.g., IM, and a MEK inhibitor, e.g., trametinib.
    Type: Application
    Filed: May 14, 2015
    Publication date: June 29, 2017
    Applicant: University of Massachusetts
    Inventors: Michael R. Green, Leyuan Ma